Senses Disorder TRIZ Cases

Pre-primed nasal micropellets deliver naloxone hydrochloride to reverse opioid overdose while minimizing drug loss from the nasal cavity.

Formula I oxadiazole derivatives modulate metabotropic glutamate receptor 2 activity to treat neurological disorders lacking effective current treatments.

Substituted thiadiazine compounds inhibit Met kinase signal transduction, addressing limited efficacy and adverse effects of existing kinase inhibitors.

Vitamin E-TPGS solubilizes curcumin in liposomes, enabling 0.2 micron filtration sterilization without ocular cytotoxicity.

Novel indolizine derivatives inhibit HIF prolyl hydroxylase to stabilize hypoxia-inducible factor and increase erythropoietin levels.

Combining acetyl L-carnitine with antihypertensive drugs increases insulin sensitivity in pre-diabetic patients.

Bis aryl analogs activate Nrf2 pathways to reduce inflammation and promote tissue repair in COPD and kidney disease treatments.

Cyclopentane derivatives target the EP2 receptor to reduce intraocular pressure while minimizing ocular surface hyperemia.

Synthesized N-heteroaryl analogs selectively target the mitochondrial PINK1 pathway to treat kidney disease, fibrosis, and reperfusion injuries.

Pre-formed macromolecular blocks bridge vascular and mesenchymal cells to resolve the contradiction between production time and structure size.

EndoS enzyme hydrolyzes the asparagine-linked glycan on IgG antibodies, removing pathogenic effector functions and neutralizing arthritis-inducing capacity.

Lyophilized Lysyl-Prolyl-Threonine formulations control pH between 3.0 and 5.0 to prevent degradation into diketopiperazine.

An insoluble polymeric matrix implant sustains drug release in the eye sulcus, avoiding repeated injections and fibrotic reactions.

Acetylated and D-amino acid modified peptides inhibit angiogenesis by blocking VEGF interactions, extending half-life to treat cancer.

Quinazoline compounds with benzofuran groups suppress angiogenesis by inhibiting kinase insert domain receptor activity to treat disorders.

Lentivirus nanoparticles use scaffold-optimized single guide RNAs to boost Cas9 affinity, reducing off-target DNA cleavage and immune activation.

A bioactive formulation of adipose-derived stem cell conditioned medium treats dry eye syndrome by delivering paracrine factors.

Isopropyl pyridyl aminoacetic acid acts as an EP2 agonist to lower intraocular pressure rapidly.

Constant-rate cooling creates uniform microparticles that reduce systemic absorption while maintaining stability against packaging degradation.

Antisense oligonucleotides bind trinucleotide repeat expansions to release sequestered proteins, reducing RNA foci without invasive surgery.

Converting bromfenac sodium to organic salts improves transdermal absorption and tissue distribution while maintaining analgesic efficacy.

Small molecule PHD inhibitors stabilize hypoxia-inducible factor, reducing inflammation and promoting tissue repair despite structural development constraints.

Modified adenosine compounds inhibit protein kinase activity to reduce side effects while maintaining therapeutic efficacy.

Dialyzed chitosan compositions resolve toxicity and strength trade-offs in tissue adhesives by providing safe, programmable drug delivery.

Substituted triazine derivatives resolve selectivity and potency trade-offs by targeting specific PI3K isoforms for therapeutic applications.

Intravitreal lysine acetylsalicylate bypasses systemic circulation to reduce inflammatory markers and improve vascular integrity in diabetic retinopathy.

Covalent bonding stabilizes polymer nanocarriers against premature degradation at the injection site, enabling reliable subcutaneous administration.

Targeted nutrient dosing addresses age-related absorption declines while preventing vitamin toxicity risks associated with megadose therapies.

Short peptides bind End Binding Protein 3 to block vascular leakage, resolving toxicity limits of existing anti-VEGF therapies.

Adjusting the polymer to drug concentration ratio in biodegradable microparticles reduces initial burst release while sustaining therapeutic duration.

SYL040012 siRNA degrades ADRB2 mRNA, lowering intraocular pressure while avoiding systemic side effects.

Pyrazinone derivatives inhibit p38 kinase to reduce lung inflammation and cytokine release, addressing steroid resistance in respiratory disease therapy.

Hydroxypyrrolidine scaffolds expand the range of applicable target proteins while maintaining high degradation effectiveness through optimized linker design.

CSF1R inhibition depletes endogenous microglia to resolve low chimerism in hematopoietic stem cell transplantation.

Cell-free fat extract promotes M1 to M2 macrophage transformation, reducing inflammation and treating diabetes complications.

Plasminogen converts to plasmin to accelerate tympanic membrane healing while minimizing scar tissue formation.

Engineered monoclonal antibodies bind human thyrotropin receptor epitopes with high affinity, resolving limited efficacy in thyroid autoimmune diagnostics.

Imidazolidine carboxamide derivatives resolve solubility-stability trade-offs via local quality modifications to effectively inhibit endothelial lipase.

Segmented antibody formats improve therapeutic duration while reducing immunogenicity.

Saponins form micelles to solubilize hydrophobic drugs, avoiding high viscosity and precipitation issues.

New small molecule inhibitors target LIMK and ROCK kinases, expanding treatment options for cancers and glaucoma.

A method for inducing dual-activated T cells using IFN-gamma, IL-2, and virus antigen peptide mixtures.

Acidic pH adjustment prevents ketotifen oxidation by hydrogen peroxide, ensuring preservative effectiveness without drug degradation.

Adjusting metformin and SGLT2 inhibitor layer weight ratios prevents cracking and cross-contamination during tablet manufacturing.

Pyridine, pyrimidine, and pyrazine compounds inhibit Bruton's tyrosine kinase to treat autoimmune diseases while minimizing off-target effects.

Substituted bicyclic compounds bind BET proteins to inhibit inflammatory cytokine expression and oncogenic transcription.

Imide and acylurea derivatives selectively modulate glucocorticoid receptor activity, separating therapeutic efficacy from adverse side effects.

Mucin-targeting aptamers on liposomes direct Cyclosporin A to the corneal epithelium, bypassing conjunctival absorption and extending retention time.